- Home
- BTMD vs VTYX Comparison
BTMD vs VTYX Comparison
Compare BTMD & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- VTYX
- Stock Information
- Founded
- BTMD 2012
- VTYX 2018
- Country
- BTMD United States
- VTYX United States
- Employees
- BTMD N/A
- VTYX N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- BTMD Health Care
- VTYX Health Care
- Exchange
- BTMD Nasdaq
- VTYX Nasdaq
- Market Cap
- BTMD 198.2M
- VTYX 184.6M
- IPO Year
- BTMD N/A
- VTYX 2021
- Fundamental
- Price
- BTMD $5.91
- VTYX $2.30
- Analyst Decision
- BTMD Strong Buy
- VTYX Buy
- Analyst Count
- BTMD 5
- VTYX 5
- Target Price
- BTMD $9.11
- VTYX $8.40
- AVG Volume (30 Days)
- BTMD 152.7K
- VTYX 2.3M
- Earning Date
- BTMD 11-12-2024
- VTYX 11-07-2024
- Dividend Yield
- BTMD N/A
- VTYX N/A
- EPS Growth
- BTMD N/A
- VTYX N/A
- EPS
- BTMD 0.21
- VTYX N/A
- Revenue
- BTMD $193,060,000.00
- VTYX N/A
- Revenue This Year
- BTMD $9.27
- VTYX N/A
- Revenue Next Year
- BTMD $14.82
- VTYX N/A
- P/E Ratio
- BTMD $29.01
- VTYX N/A
- Revenue Growth
- BTMD 4.84
- VTYX N/A
- 52 Week Low
- BTMD $3.65
- VTYX $1.67
- 52 Week High
- BTMD $8.44
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- BTMD 39.82
- VTYX 47.68
- Support Level
- BTMD $6.21
- VTYX $2.21
- Resistance Level
- BTMD $6.60
- VTYX $2.54
- Average True Range (ATR)
- BTMD 0.31
- VTYX 0.27
- MACD
- BTMD -0.11
- VTYX -0.05
- Stochastic Oscillator
- BTMD 0.81
- VTYX 8.02
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.